Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Therapy With Semaglutide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes: a Multi-center Randomized Controlled Trial

NCT06946628 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06946628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06946628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Therapy With Semaglutide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes: a Multi-center Randomized Controlled Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 1, 2025
Completion date
December 31, 2030
Enrollment
296 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus